143 related articles for article (PubMed ID: 34957030)
1. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
2. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
3. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
Rattanavipapong W; Anothaisintawee T; Teerawattananon Y
PLoS One; 2018; 13(2):e0193112. PubMed ID: 29466415
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
Stahmeyer JT; Rossol S; Liersch S; Guerra I; Krauth C
PLoS One; 2017; 12(1):e0169401. PubMed ID: 28046099
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
6. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Chen GF; Wei L; Chen J; Duan ZP; Dou XG; Xie Q; Zhang WH; Lu LG; Fan JG; Cheng J; Wang GQ; Ren H; Wang JP; Yang XX; Jia ZS; Fu QC; Wang XJ; Shang J; Zhang YX; Han Y; Du N; Shao Q; Ji D; Li F; Li B; Liu JL; Niu XX; Wang C; Wu V; Wong A; Wang YD; Hou JL; Jia JD; Zhuang H; Lau G
PLoS One; 2016; 11(6):e0155934. PubMed ID: 27276081
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors.
Arshad M; Wei F; Nelsen DA
Antivir Ther; 2015; 20(8):827-33. PubMed ID: 26555064
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan.
Mushtaq S; Akhter TS; Khan A; Sohail A; Khan A; Manzoor S
Front Pharmacol; 2020; 11():550205. PubMed ID: 32982753
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
10. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
[TBL] [Abstract][Full Text] [Related]
11. Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Jay JS; Patterson JA; Zhang Y; Ijioma SC; Carroll NV; Holdford DA; Sterling RK; Gupta G; Yakubu I
J Am Pharm Assoc (2003); 2023; 63(6):1700-1705.e4. PubMed ID: 37414279
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY
Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus.
McEwan P; Webster S; Ward T; Brenner M; Kalsekar A; Yuan Y
Cost Eff Resour Alloc; 2017; 15():15. PubMed ID: 28736505
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Rein DB; Wittenborn JS; Smith BD; Liffmann DK; Ward JW
Clin Infect Dis; 2015 Jul; 61(2):157-68. PubMed ID: 25778747
[TBL] [Abstract][Full Text] [Related]
16. Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD.
Hoyt JE; Teja N; Jiang T; Rozema L; Gui J; Watts BV; Shiner B; Gradus JL
J Dual Diagn; 2022; 18(4):185-198. PubMed ID: 36151743
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
Miranda AC; Mendez J; Serrão R; Vale F; Manata MJ; Pinto S; Gomes A; Valente C; Pacheco P; Pazos R; Pereira R; Martins A; Germano I; Rocha S; Reis AP; Sarmento-Castro R
J Viral Hepat; 2020 Jul; 27(7):715-720. PubMed ID: 32096268
[TBL] [Abstract][Full Text] [Related]
18. Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.
Westerhout KY; Bouwmeester W; Duchesne I; Pisini M; Piena MA; Damele F; Gueron B; Treur M; Belsey J
Clinicoecon Outcomes Res; 2017; 9():163-172. PubMed ID: 28280374
[TBL] [Abstract][Full Text] [Related]
19. Enhancing our understanding of current therapies for hepatitis C virus (HCV).
Gogela NA; Lin MV; Wisocky JL; Chung RT
Curr HIV/AIDS Rep; 2015 Mar; 12(1):68-78. PubMed ID: 25761432
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
